سعر Innohep anti-xa 20.000 i.u./ml 10 vial 2022

Innohep (20,000 anti-Xa IU/ml) solution for injection (vial), 10 multi-dose vials: tinzaparin sodium, a low molecular weight heparin by LEO Pharma, used for treatment of venous thromboembolism.

• Treatment of venous thrombosis and thromboembolic disease including deep vein thrombosis and pulmonary embolism in adults.Population: Adultselectronic medicines compendium (emc), UK
• Extended treatment of venous thromboembolism and prevention of recurrences in adult patients with active cancer.Population: Adultselectronic medicines compendium (emc), UK

• Common: haemorrhage, haematoma, anaemia (incl. haemoglobin decreased) and injection-site reactions. Uncommon: thrombocytopenia type I, hypersensitivity, bruising/purpura, increased liver enzymes, dermatitis, rash, pruritus. Rare: HIT type II, thrombocytosis, anaphylaxis, hyperkalaemia, toxic skin eruption incl. Stevens-Johnson syndrome, skin necrosis, angioedema, urticaria, osteoporosis with long-term use, priapism.International label, same formulation · electronic medicines compendium (emc), UK

• Hypersensitivity to tinzaparin or any excipient.International label, same formulation · electronic medicines compendium (emc), UK
• Current or history of immune-mediated heparin-induced thrombocytopenia (type II).International label, same formulation · electronic medicines compendium (emc), UK
• Active major haemorrhage or conditions predisposing to major haemorrhage.International label, same formulation · electronic medicines compendium (emc), UK

• Haemorrhage risk: use with caution; avoid or carefully monitor combination with drugs affecting platelets or coagulation; avoid intramuscular injections.International label, same formulation · electronic medicines compendium (emc), UK
• Heparin-induced thrombocytopenia: measure platelet count before and periodically during treatment; discontinue if HIT type II develops.International label, same formulation · electronic medicines compendium (emc), UK
• Hyperkalaemia via aldosterone suppression, particularly with diabetes, chronic renal failure, metabolic acidosis, potassium-raising drugs or long-term use; monitor potassium in patients at risk.International label, same formulation · electronic medicines compendium (emc), UK

• Drugs affecting coagulation or platelet function (aspirin and other NSAIDs, thrombolytics, vitamin K antagonists, activated protein C, direct factor Xa and IIa inhibitors)May enhance the anticoagulant effect of tinzaparin; avoid or monitor carefully.electronic medicines compendium (emc), UK

• Data from more than 2,200 pregnancy outcomes show no malformative or feto/neonatal toxicity; tinzaparin does not cross the placenta and can be used in all trimesters if clinically needed, under specialist involvement; not recommended in pregnant women with prosthetic heart valves.International label, same formulation · electronic medicines compendium (emc), UK
• Vials contain benzyl alcohol, which may cross the placenta; benzyl-alcohol-free syringes should be used during pregnancy.International label, same formulation · electronic medicines compendium (emc), UK
• Passage into breast milk is expected to be very low and oral absorption by the infant very unlikely; tinzaparin can be used during breastfeeding. Benzyl-alcohol-free pre-filled syringes are preferred over vials.International label, same formulation · electronic medicines compendium (emc), UK

• Tinzaparin sodium: Potentiates antithrombin III inhibition of activated coagulation factors, primarily factor Xa (anti-Xa/anti-IIa ratio 1.5-2.5); mass-average molecular mass about 6,500 daltons (UK SmPC 5.1).